Founder and CEO John Kelly speaks to SBS World News about how Atomo Diagostics is using technology from its HIV rapid diagnostic tests (RDTs) to create a product that will test for Covid-19. [embed]https://vimeo.com/402583336[/embed] ...
Today, Founder and CEO of Atomo Diagnostics, John Kelly, was interviewed by Bloomberg on the subject of rapid diagnostic testing for coronavirus (COVID-19). John Kelly explained how Atomo is working with OEM partners in China, the USA, and Europe to bring to market rapid diagnostic tests...
Today, Atomo Diagnostics announced it was working with potential OEM customers to develop rapid self-tests for COVID-19 that could deliver results to patients in as little as 15 minutes, and be deployed in the field without the need for expensive laboratory equipment or extensive clinical...
Today, Atomo Diagnostics and partner Mylan have jointly announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO PQ). The WHO PQ process includes a rigorous evaluation of the test’s...
Today, in a joint press release, Access Bio Inc. and Atomo Diagnostics have announced the development of a best-in-class rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). It is expected that the new self-tests, along with a professional use version, will be made...
Today, Atomo Diagnostics announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA). It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator. Addressing the media following the announcement, Founder and CEO of Atomo Diagnostics,...
Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The self-tests, which use the innovative AtomoRapid platform, will allow individuals to confidently screen themselves...
Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage...
Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at...
Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets. Atomo will supply its award-winning AtomoRapid™ lateral flow diagnostic test platforms for use with Access Bio’s in vitro HIV rapid...
Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined by Unitaid and The Global Fund to expedite access to innovative diagnostic products in advance...
Atomo Diagnostics' CEO John Kelly announced today that the Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. The company is now actively engaging with commercialisation and distribution partners to make the test widely available in European and other global markets during 2018...
Atomo Diagnostics has today announced that Doris-Ann Williams MBE, has been appointed to join its Board of Directors. Doris-Ann is Chief Executive of the British In Vitro Diagnostics Association (BIVDA) and has worked in the IVD sector for more than 30 years, initially in R&D and...
Delighted to welcome new investors for 2017, earlier this month Atomo Diagnostics announced backing from Grand Challenges Canada (GCC). Investment from the Canadian Government-funded agency totalling US$1 million (A$1.31 million, C$1.32 million), in recognition of a ‘bold idea with big impact in global health’, will help...
The December issue of Australian Biochemist is out and Atomo Diagnostics is highlighted in its Special Technical Feature on microfluidics and molecular diagnostic technologies that have revolutionised testing for infectious diseases and genetics. Atomo is named as one of leading Australian companies working in this space,...
Next week, from 14 to 17 November, the team from Atomo Diagnostics will be at the world's largest annual medical trade fair - Medica. The 4-day event, held in Dusseldorf, Germany, is expected to attract over 130,000 healthcare industry professionals from more than 120 countries. We will...
Atomo Diagnostics is delighted to announce that we have been working with French biotechnology company, NG Biotech, to develop the world’s first fully-integrated blood-based rapid test for detection of hCG levels in pregnancy. The new product, NG-Test® Blood Precision hCG, will be unveiled this month...
In the past 12 months Atomo has secured grant funding to commercialise various tests using its technology, including a grant from the NSW Medical Devices Fund for a digital HIV Self-Test and a grant from the Australian Commonwealth for a range of tropical fever tests. Today...
Atomo Diagnostics will be exhibiting at the 21st International AIDS Conference held in Durban, South Africa later this month (18 to 22 July). The conference, also known as AIDS 2016, is the world’s largest gathering of policy makers, healthcare service providers, not-for-profit groups and individuals seeking to...
Atomo Diagnostics is delighted to announce the company has won the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge. The win, which comes with $100, 000 in funding to deliver a 'proof of concept' program, was announced by the Premier of Queensland, Annastacia Palaszczuk, at the...
Atomo is delighted to announce that the company has secured $1.38 million in grant funding from the Australian Government to assist in the development and commercialisation of new rapid tests for the detection of dengue and chikungunya viruses. Half the world’s population live in areas at risk...
Atomo’s CEO describes the company’s innovations in rapid diagnostics on Sky News Atomo Group CEO, John Kelly, was invited to talk with Peter Switzer on Sky News on 25 July 2016 to discuss the company’s continuing success in the diagnostic technology sector. Atomo has attracted high-profile support...
Atomo Secures US$6M from the Global Health Investment Fund Atomo Secures US$6M Investment From GHIF_140116 The investment will support scale up of Atomo’s global health activities, focusing on continued rollout of its award winning AtomoRapid™ HIV test and launch of an affordable HIV self-test offering unmatched performance January...
Atomo Diagnostics is delighted to announce that the company has been awarded a grant of A$1.8 million (US$1.3M) from the New South Wales Medical Device Fund 2015-2016 for the development of a self-test for rapid detection of HIV. The Atomo HIV Self Test will be...
Atomo Diagnostics is delighted to have received the ‘Innovation in Export’ Award at the 2015 Premier’s NSW Export Awards, hosted by the Export Council of Australia. The award recognises a NSW company that has made innovation an integral part of their exporting process. Atomo currently exports...
The team at Atomo Diagnostics is delighted to announce that it has been selected as the winner of the Johnson & Johnson Innovation Industry Excellence, Emerging Company of the Year Award for 2014. The award was announced as part of the AusBiotech opening address, held at...
Metropolitan Health integrates AtomoRapid HIV into HIV YourLife Programme In corporate South Africa, testing for HIV infection is still considered a contentious issue. However, it is critical for companies to encourage employees to become aware of their status. The HIV/AIDS epidemic is one of the greatest...
AtomoRapid™ HIV has been selected as a finalist in the In Vitro Diagnostic Products and Systems Category at the 17th Medical Design Excellence Awards (MDEA), held in New York this week. The winners will be announced at an awards ceremony tomorrow night in New York. The...
The SMART 100 Index was created by Anthill Magazine to identify and rank Australia’s 100 most innovative products and services, proving to be one of the largest surveys of its kind in Australia - and the company is delighted to announce that AtomoRapid™ HIV topped...
Atomo is delighted to announce the opening of its first African office in South Africa. Brad Mears, previously the CEO of the SA Business Coalition on HIV/Aids (SABCOHA) has been appointed to the Atomo team as the Managing Director of their Africa office. Brad held the...